Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307398 · ClinicalTrials.gov registry record · Phase 3
Anecortave Acetate Risk-Reduction Trial (AART)
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,596
- Enrollment target
NCT00307398 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 2,596 participants.
The verdict
NCT00307398, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,596 participants
- Enrollment target
Study Summary
A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Interventions
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,596 participants |
| Start Date | 2004-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307398
The ClinicalTrials.gov registry entry for NCT00307398 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anecortave Acetate Vehicle is the first listed.
NCT00307398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00307398 about?
NCT00307398 is a clinical study titled "Anecortave Acetate Risk-Reduction Trial (AART)". A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
What is the current status of trial NCT00307398?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,596 participants. The study started on 2004-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00307398?
The interventions under investigation include: Anecortave Acetate Vehicle (OTHER), Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg (DRUG).
Who is sponsoring clinical trial NCT00307398?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.